Congenital myasthenic syndromes (CMSs) are genetic disorders characterized by a faulty neuromuscular junction causing muscle weakness with or without respiratory and oculomotor involvement. Congenital myopathies (CMs) can present similarly to CMS but are secondary to muscle protein defects. CMSs cause muscular weakness, hypotonia, and ptosis and can respond to treatment 1, 2 ; CMs have no proven therapies. We present a patient with DOK7 CMS, previously diagnosed as CM for 25 years.
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Case report
A 29-year-old man presented for evaluation of progressive muscle weakness that had made him nonambulatory for more than 10 years. He had delayed motor milestones, could not run, and had difficulty walking and getting up from the ground at age 2 years. He used a walker by age 6 years. He was diagnosed with Duane syndrome (congenital horizontal eye movement limitation) and congenital myopathy at age 4 years (muscle biopsy showed type 1 fiber predominance and mild type 2 fiber atrophy, without tubular aggregates in nicotinamide adenine dinucleotide [NADH] or electron microscopy). He had strabismus surgery at age 5 years. Medical, surgical, familial, and social histories were otherwise noncontributory.
He had mild bilateral ptosis and mild facial and 4/5 shoulder shrug weakness. On strength testing, the deltoids, biceps, triceps, and hip flexors were 3/5 bilaterally; finger/wrist flexors and extensors and hand intrinsics were 5/5 bilaterally; knee flexors and extensors, foot dorsiflexion, and plantar flexion were 4/5 bilaterally. Reflexes were absent. He could walk only a few steps. Mental status, language, and sensation were normal.
Given his progressive weakness, bilateral eyelid ptosis, and nonspecific muscle biopsy results, we re-evaluated him for a neuromuscular junction defect. Two-hertz repetitive nerve stimulation (RNS) of the right median and accessory nerves showed marked compound muscle action potential (CMAP) decremental responses, which worsened after 1 minute of exercise (figure). His acetylcholine receptor antibody was negative, and CK was 82. Genetic testing revealed 2 known pathogenic mutations, c.1124_1127dupTGCC (p.Ala378Serfs*30) and c.1623dupC (p.Ser422Leufs*97), in the DOK7 gene. Before genetic test results were available, he took pyridostigmine 60 mg TID for 9 months, which worsened his weakness. Afterward, he started albuterol 5 mg PO TID, and 3 weeks later, he could walk up to 100 feet and had normal lower extremity muscle strength. 
Discussion

PRACTICAL IMPLICATIONS
Consider congenital myasthenic syndrome and perform repetitive nerve stimulation in patients with congenital myopathy or congenital muscular dystrophy and progressive weakness and extraocular movement abnormality or eyelid ptosis.
e40 Copyright © 2018 American Academy of Neurology eyelid ptosis, extraocular movement abnormality, and increasing weakness with exertion, but this is not always clear from history. Therefore, it is necessary to perform further testing such as muscle biopsy or RNS. In CM, muscle biopsy often shows features such as central cores, central nuclei, or nemaline rods, but many have nonspecific findings. Muscle biopsy in CMS will show a milder or nonspecific dystrophic pattern. RNS is the most helpful test, as it will show marked CMAP decremental response in CMS. Genetic testing identifies the underlying gene defect in up to 50% of cases, 1 and guides treatment, as some patients worsen with pyridostigmine (commonly used for neuromuscular junction disorders). If there is a suspicion of DOK7 CMS, improvement with a trial of salbutamol (albuterol) usually supports the diagnosis. 2 The DOK7 gene encodes the skeletal muscle adaptor protein DOK-7. This protein autophosphorylates MuSK and causes aggregation of acetylcholine receptors on the motor end plate. Without this protein, the receptors cannot properly aggregate, causing neuromuscular transmission failure and weakness. Patients usually present by age 5 years (some cases start in late adolescence and adulthood) with limb-girdle weakness without ophthalmoplegia. 2 Ptosis is commonly present. Progressive respiratory impairment typically occurs throughout life. Pyridostigmine does not help and can make symptoms worse. Unless treated, symptoms continue to progress with time. Our patient showed improvement with albuterol (salbutamol), which is the most effective treatment of DOK7 CMS. Salbutamol is a beta-2 agonist that works by bypassing the step in the receptor aggregation pathway that requires DOK-7 so that the acetylcholine receptors are still able to aggregate and function properly at the neuromuscular junction. Studies have demonstrated that oral salbutamol increased stamina and function in 1 month. It has even shown to make nonambulatory children walk again. 4 Other DOK7 CMS cases with delayed diagnosis have been reported in the literature (table) .
Conclusion
Consider CMS in patients with congenital or early-onset muscular weakness, eyelid ptosis, fluctuating symptoms, and/ or improvement of weakness with salbutamol or "asthma medications." RNS and genetic testing are paramount in achieving an early diagnosis and initiating treatment to prevent further muscle injury and disability.
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